Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.50K | 45.20K | 87.50K | 121.50K | 11.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.50K | 45.20K | 87.50K | 121.50K | 11.00K |
| Cost of Revenue | 800.00 | -- | 4.00K | 4.90K | 4.00K |
| Gross Profit | 700.00 | 45.20K | 83.50K | 116.60K | 6.90K |
| SG&A Expenses | 473.50K | 1.18M | 612.80K | 599.60K | 503.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 474.30K | 1.18M | 616.80K | 604.50K | 507.70K |
| Operating Income | -472.80K | -1.13M | -529.30K | -483.10K | -496.80K |
| Income Before Tax | -766.20K | 2.06M | 7.23M | -12.93M | -603.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -766.20K | 2.06M | 7.23M | -12.93M | -603.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -766.20K | 2.06M | 7.23M | -12.93M | -603.40K |
| EBIT | -472.80K | -1.13M | -529.30K | -483.10K | -496.80K |
| EBITDA | -311.10K | -969.60K | -367.60K | -321.30K | -335.10K |
| EPS Basic | 0.00 | 0.01 | 0.03 | -0.07 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.02 | -0.04 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.07 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 |
| Average Basic Shares Outstanding | 298.39M | 276.33M | 251.36M | 189.21M | 153.60M |
| Average Diluted Shares Outstanding | 298.39M | 1.35B | 1.74B | 189.21M | 153.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
